Rivastigmine Patch
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Delirium
Conditions
Delirium, Postoperative Cognitive Dysfunction
Trial Timeline
Dec 1, 2008 → Oct 1, 2010
NCT ID
NCT00835159About Rivastigmine Patch
Rivastigmine Patch is a approved stage product being developed by Novartis for Delirium. The current trial status is completed. This product is registered under clinical trial identifier NCT00835159. Target conditions include Delirium, Postoperative Cognitive Dysfunction.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02703636 | Approved | Completed |
| NCT01380288 | Pre-clinical | Completed |
| NCT00835159 | Approved | Completed |
Competing Products
17 competing products in Delirium
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lemborexant 5 mg + Control (placebo) group | Eisai | Phase 2 | 52 |
| Suvorexant + Placebo | Merck | Phase 3 | 77 |
| Suvorexant 20 mg + Placebo | Merck | Phase 2 | 52 |
| Rivastigmine + Placebo | Novartis | Approved | 85 |
| Rivastigmine prevention of delirium | Novartis | Phase 3 | 77 |
| Rivastigmine transdermal patch + placebo patch | Novartis | Phase 3 | 77 |
| Dexmedetomidine + Placebo | Pfizer | Phase 3 | 76 |
| Parecoxib | Pfizer | Approved | 84 |
| Dexmedetomidine + Placebo | Pfizer | Phase 3 | 76 |
| Pregabalin | Pfizer | Phase 3 | 76 |
| Dexmedetomidine + Midazolam | Pfizer | Phase 3 | 76 |
| Propofol + Dexmedetomidine | Pfizer | Pre-clinical | 22 |
| Dexmedetomidine + Saline placebo | Pfizer | Phase 2/3 | 64 |
| Cyclopofol + Propofol | Haisco Pharmaceutical Group | Approved | 82 |
| Dexmedetomidine + Sodium chloride 0.9% | Baxter | Phase 3 | 74 |
| Dexmedetomidine Hydrochloride Group | Brain Biotech | Approved | 77 |
| Dexmedetomidine sublingual film | BioXcel Therapeutics | Phase 2 | 44 |